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Inflammatory bowel diseases (IBDs) are complex, multifactorial disorders characterized 
by chronic relapsing intestinal inflammation. Although etiology remains largely unknown, 
recent research has suggested that genetic factors, environment, microbiota, and immune 
response are involved in the pathogenesis. Epidemiological evidence for a genetic con-
tribution is defined: 15% of patients with Crohn’s Disease (CD) have an affected family 
member with IBD, and twin studies for CD have shown 50% concordance in monozygotic 
twins compared to <10% in dizygotics. The most recent and largest genetic association 
studies, which employed genome-wide association data for over 75,000 patients and 
controls, identified 163 susceptibility loci for IBD. More recently, a trans-ethnic analysis, 
including over 20,000 individuals, identified an additional 38 new IBD loci. Although most 
cases are correlated with polygenic contribution toward genetic susceptibility, there is a 
spectrum of rare genetic disorders that can contribute to early-onset IBD (before 5 years) 
or very early onset IBD (before 2  years). Genetic variants that cause these disorders 
have a wide effect on gene function. These variants are so rare in allele frequency that 
the genetic signals are not detected in genome-wide association studies of patients with 
IBD. With recent advances in sequencing techniques, ~50 genetic disorders have been 
identified and associated with IBD-like immunopathology. Monogenic defects have been 
found to alter intestinal immune homeostasis through many mechanisms. Candidate 
gene resequencing should be carried out in early-onset patients in clinical practice. The 
evidence that genetic factors contribute in small part to disease pathogenesis confirms 
the important role of microbial and environmental factors. Epigenetic factors can mediate 
interactions between environment and genome. Epigenetic mechanisms could affect 
development and progression of IBD. Epigenomics is an emerging field, and future 
studies could provide new insight into the pathogenesis of IBD.
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inTRODUCTiOn
Inflammatory Bowel Diseases (IBDs) are complex, multifactorial disorders characterized by chronic 
relapsing intestinal inflammation. The two major subtypes of IBD are Ulcerative Colitis (UC) and 
Crohn’s Disease (CD).
Ulcerative Colitis and CD are important worldwide health problems, with an incidence in Europe 
of 12.7 and 24.3 per 100,000 person-years, respectively, and prevalence of 0.5 and 1.0%.
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The incidence of IBDs is continually growing among children 
and adults, all over the world (1).
Although the exact etiology is still not completely known, 
recent studies have indicated that personal genetic susceptibility, 
environment, intestinal microbiota, and immune system are all 
involved in the pathogenesis of IBDs (Figure 1).
The heritability model of CD and UC is still unknown, but 
many genetic and environmental factors are likely to be involved. 
These conditions tend to occur in multiple familial cases, and 
having an affected relative is an important risk factor for the onset 
of IBD.
Population-based studies have provided compelling evidence 
that genetic factors contribute to the pathogenesis of IBD; an 
8- to 10-fold greater risk of IBD among relatives of UC and CD 
probands has been demonstrated and, most importantly, that 
there is concordance between twins (2).
Twin studies have provided the best evidence for genetic 
predisposition to IBD, which is stronger for CD than UC. In par-
ticular, twin and family studies for IBD have shown that a child 
has a 26-fold increased risk for developing CD when another 
sibling already has it, and the risk is ninefold increased in the 
case of UC (3).
However, the fact that genetic factors account for only a part 
of general disease variance indicates that microbiota and environ-
ment may interact with genetic susceptibility in the pathogenesis 
of IBD.
The adaptive immune system has been classically considered 
to play the main role in the pathogenesis of IBD. Recent research 
in genetics and immunology has confirmed that the innate 
immune system maintains great importance in inducing gut 
inflammation.
New advances in understanding IBD pathogenesis explain 
important disease mechanisms, including not only the innate 
and adaptive immunity, but also interactions between genetic, 
microbial, and environmental factors (4).
Genetics
Epigenetics
MiRNAs
GWAS
~ 200 loci
NGS
WES/WGS
Environment
Gut Microbiota
Inlammation
Immune system
Autophagy
FiGURe 1 | The complex pathogenesis of inflammatory bowel 
diseases.
GeneTiCS AnD PATHOGeneSiS
Over the past few decades, there have been important advances 
in our understanding of genetic contributions to IBD. This is due 
to technological progress in genetic testing and DNA sequencing 
that has allowed many genome-wide association studies (GWAS), 
which have identified new single nucleotide polymorphisms 
(SNPs) (4, 5).
Nucleotide-binding oligomerization domain containing 2 
(NOD2) was the first susceptibility gene for CD discovered in 
2001. This gene codes for a protein that acts as an intracellular 
receptor for bacterial products in monocytes and transduces 
signals leading to NFkB activation. The activation of NOD2 with 
muramyl dipeptide induces autophagy in dendritic cells (DCs). 
DCs from CD patients with susceptibility variants in NOD2 
gene are deficient in autophagy induction and also show reduced 
localization of bacteria in autophagolysosomes (6).
Genome-wide association studies have identified and con-
firmed many susceptibility loci for IBDs. The identification of 
susceptibility loci has enhanced understanding of causes of the 
disorder by providing important clues in crucial and disturbed 
pathways of the intestinal immune system (7).
Genetic analyses have reported two other autophagy-related 
genes, IRGM and ATG16L1, showing an important role for 
autophagy in immune responses in IBD. Genetic variants that 
have been found to confer an increased risk of CD indicate the 
importance of innate immunity, autophagy, and phagocytosis in 
its pathogenesis.
Other genes, like IL23R and PTPN2, are also associated 
with autoimmune disease, suggesting another aspect of Crohn’s 
pathogenesis.
Recent progress in the genetics of IBD can explain the under-
lying pathogenesis of the disease.
Conventional IBD is a group of polygenic disorders in which 
hundred(s) of susceptibility loci contribute to the overall risk of 
disease.
The most recent and largest genetic association study, which 
employed genome-wide association data for over 75,000 adoles-
cent and adult-onset IBD patients and controls, identified 163 
susceptibility loci for IBD, encompassing ~300 potential candidate 
genes. Of these 163 loci, 110 conferred risk to both IBD subtypes, 
whereas 30 loci where unique to CD and 23 loci were unique to 
UC. More recently, a trans-ethnic analysis including over 20,000 
individuals of European and non-European ancestry identified 
an additional 38 new IBD loci, highlighting shared genetic risk 
across populations and increasing the number of known IBD risk 
loci to 200 (8, 9).
The evidence of shared IBD risk loci across diverse populations 
suggests that combining genotype data from cohorts of different 
ancestry will enable the detection of additional IBD-associated 
loci.
However, all identified loci individually contribute only a 
small percentage of the expected heritability in IBD (3).
The increasing number of susceptibility gene loci described 
in IBD indicates that genetic components are important factors 
involved in the disease pathogenesis. Identified genetic factors 
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account for only a small proportion of the disease variance: 13.1% 
for CD and 8.2% for UC. Overall, explainable susceptibility loci 
and genetic risk factors discovered so far, account for only 20–25% 
of the heritability (genetic risk) (8, 10).
MOnOGeniC FORMS AnD veRY  
eARLY-OnSeT iBD
Approximately 20–25% of patients with IBD are diagnosed before 
16 years old. The onset of intestinal inflammation in children can 
affect development and growth. Age of onset can also provide 
information on type of IBD and associated genetic features.
Although most cases of IBD are correlated with a polygenic 
contribution toward genetic susceptibility, there is a spectrum of 
rare genetic disorders that produce IBD-like intestinal inflamma-
tion (11).
Early-onset inflammatory bowel diseases (EO-IBD) (before 
5  years) and very-early-onset inflammatory bowel diseases 
(VEO-IBD) (before 2 years) are rare, particularly severe disease 
presentations. Few case series have reported on early-onset of 
IBDs, often described as CD or CD-like, but starting within the 
first year of life with typical characteristics of CD. The majority 
of VEO-IBD are caused by genetic defects (monogenic diseases).
The genetic variants that cause these disorders have a wide effect 
on gene function. These variants are so rare in allele frequency 
that the genetic signals are not detected in GWAS of patients with 
IBD. With recent advances in genetic mapping and sequencing 
techniques and increasing awareness of the importance of these 
rare disorders, ~50 genetic disorders have been identified and 
associated with IBD-like immunopathology.
Monogenic defects have been found to alter intestinal immune 
homeostasis via several mechanisms.
These include disruption of the epithelial barrier and the 
epithelial response, as well as reduced clearance of bacteria by 
neutrophil granulocytes and other phagocytes. Other single-
gene defects induce hyperinflammation or autoinflammation or 
disrupted T- and B-cell selection and activation.
Hyperactivation of the immune response can result from 
defects in immune inhibitory mechanisms, such as defects in 
IL-10 signaling or dysfunctional regulatory T-cell activity (3).
The main of the IL-10 pathway within the colonic mucosa 
is confirmed by the occurrence of severe colitis during the first 
weeks of life in infants carrying mutations in IL10, IL10RA, or 
IL10RB genes. Immunosuppression has failed to correct the 
defect in this pathway, which seems to be important to control 
colon inflammation (12).
Loss-of-function defects in IL-10 and its receptor (encoded by 
IL10RA and IL10RB genes) cause VEO-IBD with perianal disease 
and folliculitis within the first months of life. All patients with 
loss-of-function mutations that prevent IL-10 signaling develop 
IBD-like immunopathology, indicating that these defects are a 
monogenic form of IBD with 100% penetrance (13, 14).
A functional IL-10 pathway is essential for immune homeo-
stasis within the colon, and defects in this cytokine or one of 
the subunits of its receptors cause extensive inflammation of 
the colon and perianal region. Thus, on a clinical basis, we can 
suspect a defect in the IL-10 pathway in children, presenting deep 
ulcerations and granuloma (CD-like), especially in consanguine-
ous families (12).
It is a challenge to diagnose the rare patients with monogenic 
IBD, but accurate genetic diagnosis is important for assessing 
prognosis, and proper treatment of patients.
This group of diseases has high morbidity, and subgroups have 
high mortality if untreated. Based on the causes, some require 
different treatment strategies from most cases of IBD. A genetic 
diagnosis should always be carried out due to the differences in 
prognosis and medical management (3).
iBD in THe eRA OF neXT-GeneRATiOn 
SeQUenCinG
Next-generation sequencing (NGS) is a new technology with 
the potential to identify every genetic variation throughout the 
human genome in a single experiment.
Next-generation sequencing technologies have revolutionized 
the field of medical genetic research and are currently being 
used to search for Mendelian disease genes, and applied for the 
diagnosis of patients with genetically heterogeneous disorders. 
This can be performed much faster and more cost efficiently than 
with traditional techniques.
It is often a less expensive option than traditional Sanger 
sequencing for diseases characterized by genetic heterogeneity. 
This is a novel approach to discover lower prevalence with higher 
effect size (15).
Because of the large amount of data that are being generated, 
bioinformatic analysis plays an important role in research and 
diagnostics (16, 17).
The two sequencing approaches for detecting variations in the 
genetic code are whole genome sequencing (WGS) and whole 
exome sequencing (WES).
Whole genome sequencing is the ultimate approach for 
detecting all genomic variations in a patient’s genome. However, 
current NGS instruments are limited in terms of throughput and 
cost efficiency and this approach is often only used for large-scale 
research studies and gene discovery projects.
Whole exome sequencing is a more cost-efficient strategy 
for novel disease gene discovery and diagnostics in human 
genetics. The protein-coding regions constitute the exome, 
~1% of the human genome or ~30  Mb, split across ~180,000 
exons. Currently, the great majority of mutations responsible 
for Mendelian diseases in humans affects sequences within the 
coding regions of exons or are located within a few nucleotides 
of the exon boundaries. Exome sequencing basically refers to 
the enrichment of sequences corresponding to all (or nearly all) 
protein-coding exons followed by next-generation sequencing.
Exome sequencing was introduced in 2009. Since then, it has 
been used to discover several hundred novel disease genes and 
has begun to significantly improve diagnostics for patients with 
rare genetic diseases. It has rapidly become one of the main tools 
for studying the genetic causes of diseases and we have learned 
much from exome sequencing.
Whole exome sequencing covers only coding areas of the 
genome, and costs less than WGS, providing higher-depth cover-
age and therefore greater certainty regarding novel discoveries. 
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But only together with subsequent functional studies on identi-
fied proteins and pathways will novel technologies elucidate 
underlying pathogenic mechanisms.
Use of WES in clinical diagnostics has grown significantly 
since clinical laboratories started performing it. Many patients 
with rare recessive and dominant disorders, who had previously 
spent years on an uninformative diagnostic odyssey, have now 
had diagnoses made through WES (16).
Interestingly, results of diagnostic applications of NGS indicate 
that there is a much wider phenotypic spectrum associated with 
mutations in many genes than was suspected from initial clinical 
definition and Sanger sequencing.
The advent of NGS techniques has allowed new large-scale 
approaches with unexpected diagnostic power. In particular, 
WES is changing the diagnostic paradigm in medical genetics 
practices.
The traditional diagnostic approach with clinical evaluation 
and laboratory analysis provides a diagnosis in ~50% of patients. 
WES offers the possibility to have an answer in most of the remain-
ing cases, providing diagnosis in another 25–30% of patients (18).
The WES approach has been successfully used to identify 
single variants in very early-onset IBD and has been quite suc-
cessful in elucidating novel monogenic forms of IBD and new 
susceptibility genes. However, many polymorphisms that affect 
disease susceptibility are located in non-coding areas of the 
genome: for this reason, the ENCODE (Encyclopedia of DNA 
Elements) project has highlighted the importance of non-coding 
regions in disease risk, trying to identify all functional elements 
in the human genome sequence (19).
ePiGeneTiCS AnD iBD
Inflammatory bowel diseases could be caused by interactions 
between the patient and the environment, in particular the 
genome, the immune system, the intestinal microbiota, and 
specific environmental factors such as the effects of breastfeeding, 
food, smoking, drugs, and so on. Epigenetics may be defined as 
mitotically heritable changes in gene expression without altering 
the DNA sequence.
Gene expression can be altered by changes to the structure 
and function of chromatin. Different cells in the body are 
characterized by different functions and different levels of 
gene expression despite each sharing the same genetic code. 
This variation in gene activity from cell to cell is achieved by 
mechanisms and processes that are collectively termed epigenet-
ics. The main epigenetic mechanisms include DNA methylation, 
histone modification, RNA interference, and the positioning of 
nucleosomes. These epigenetic mechanisms, in particular DNA 
methylation, appear to be very important in the interaction 
between environment and genome. It is potentially reversible 
and heritable over rounds of cell division (20). Variation in 
DNA methylation is a well-recognized cause of human disease 
and is likely to play a pivotal role in the cause of complex dis-
orders. Several well-known disorders of imprinting are known 
including Beckwith–Wiedemann syndrome, Temple syndrome, 
Wang–Ogata syndrome, Silver–Russell syndrome, Angelman 
syndrome, and Prader–Willi syndrome. Imprinted genes are 
thought to play an important role in fetal growth and their 
carefully regulated expression is important for normal cellular 
metabolism and human behavior.
The challenge is to identify consistent epigenetic alterations 
of etiological significance, given that epigenetic modification 
of DNA differs between tissues, occurs at different times of 
development within the same tissue and is sensitive to continual 
environmental factors.
Epigenetics has developed into one of the most promising 
concepts in all areas of biomedical research. Recent epigenetic 
studies have shown that interactions between genome and envi-
ronment play an important role in the phenotypical expression of 
diseases, explaining also the differences in disease expression in 
monozygotic twins (1).
Much evidence supports the idea that IBD is caused by a 
complex interaction between genetic mutations of multiple 
genes and environmental factors. There is growing evidence that 
epigenetic factors can play an important role in the pathogenesis 
of IBD.
A number of potential clinical applications of epigenetics in 
diagnostics and therapeutics are receiving attention. The diag-
nostic applications of epigenetics include the use of biomarkers 
to confirm diagnosis, stratify disease course and response to 
chemotherapy, and predict development of cancer (11).
DNA methylation is the most studied epigenetic modification 
and during the last decade its correlation to IBD pathogenesis 
has been well established. Several reports have suggested that 
there are significant differential DNA methylation statuses 
between normal and inflamed tissues from CD and UC patients. 
Therefore, there are evidences that the hypermethylation of many 
gene promoters is associated with IBD patients.
Genes from different molecular pathways have been studied 
but till now there is no standardized database of methylated genes 
in IBD.
DNA methylation patterns have proven to be most useful in 
the sensitive detection of disease.
DNA-methylation-based technologies have a promising 
future in both clinical diagnostics and therapeutics. DNA meth-
ylation markers have been developed using targeted candidate 
gene approaches and have applications in diagnostics, but can 
also contribute to therapeutics as predictors of therapeutic 
response (20). Further studies of epigenetic factors associated 
with IBD could lead to new therapeutic strategies, whether they 
specifically target epigenetic mechanisms or affect the pathways 
they control.
DNA methylation should be studied in depth to understand 
the molecular pathways of IBD pathogenesis, and epigenetic 
studies of IBD discussed that may have a significant impact on 
the field of IBD research.
THe eMeRGinG ROLe OF MiRnA in iBD
The field of microRNA (miRNA) research is expanding rapidly. 
MiRNAs are strongly implicated in the pathogenesis of many 
common diseases, including IBDs, playing an important role in 
the development, regulation and differentiation of the innate and 
adaptive immune system (21).
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MicroRNAs are a class of endogenous small non-coding 
single-stranded RNA molecules, ~18–24  nt long, encoded in 
genomic DNA, which act as post-transcriptional regulators of 
gene expression. The biogenesis of miRNAs goes from transcrip-
tion in the nucleus to generation of the mature miRNA in the 
cytoplasm.
MiRNA genes are located throughout the genome, either 
within intronic sequences of protein-coding genes, within 
intronic or exonic regions of non-coding RNAs, or set between 
independent transcription units (intergenic). Some miRNAs have 
their own promoters and are transcribed independently, some 
share promoters with host genes, while others are co-transcribed 
as a single primary miRNA transcript (21, 22).
It is estimated that miRNAs regulate more than 60% of 
protein-coding mRNAs and that more than one-third of human 
genes are targets for miRNA regulation.
In particular, each miRNA can target hundreds of mRNAs and 
each mRNA can be regulated by several miRNAs, resulting in 
mRNA destabilization and/or inhibition of translation.
They regulate important cellular functions such as differentia-
tion, proliferation, signal transduction, and apoptosis and exhibit 
highly specific regulated patterns of gene expression.
Emerging evidence suggests the regulation of miRNAs expres-
sion through epigenetic mechanisms such as DNA methylation, 
histone modifications, and circular RNAs (circRNAs). DNA 
methylation, the addition of methyl groups at CpG islands by 
DNA methyltransferases, is associated with transcriptional 
repression. Similarly, acetylation or deacetylation of histones may 
alter transcriptional activity. This process adds complexity to our 
understanding about regulation of gene expression (21).
Although a large number of miRNAs have been identified, 
little is known about their function (23).
There is growing evidence that miRNAs play a role in the 
induction of cancer, inflammatory, and autoimmune diseases. In 
the intestinal tract, miRNAs are involved in tissue homeostasis, 
intestinal cell differentiation, and the maintenance of intestinal 
barrier function (24).
Nowadays, research is interested in the possibility to use 
miRNAs as biomarkers and therapeutic target in IBD. There are 
emerging data from human diseases studying miRNAs as novel 
biomarkers in diagnosing and predicting disease course and 
response to therapy.
Recently, several studies have shown a differential expression 
of miRNAs in tissue samples and blood from patients with IBDs 
compared with healthy controls, suggesting that miRNAs may be 
considered as novel biomarkers of these diseases (25).
Given that CD and UC differ in their clinical presentations, 
genetic associations, gene expression patterns, and immune 
responses, differing miRNA profiles are expected for these two 
conditions.
Studies to date have identified unique miRNA expression 
profile signatures in IBD and preliminary functional analyses 
associate these deregulated miRNAs to canonical pathways 
associated with IBD pathogenesis (26).
Crohn’s Disease and Ulcerative Colitis patients have unique 
miRNA expression profiles in their target organs. While some 
differentially expressed miRNAs are common to other immune-
related disorders, most are unique.
Moreover, it has been shown that CD and UC differ not only 
in their tissue miRNA profiles, but also in their peripheral blood 
miRNA profiles. Then there are unique miRNA tissue profiles and 
distinct miRNA profiles in peripheral blood.
While UC and CD represent distinct diseases with some 
overlap, identification of distinct miRNA expression profiles may 
provide an early method to determine a patient’s disease course. 
After the functional consequences of alterations in miRNA 
expression are established, miRNA may also become the target 
of future treatments.
Further investigation about the roles of miRNAs in the human 
context will improve our knowledge of miRNAs in the pathogen-
esis and diagnosis of IBD and will be useful for the development 
of miRNA-based therapies (27).
COnCLUSiOn
The number of potential IBD susceptibility genes continues to 
increase. The increasing number of genetic loci associated with 
IBD requires other studies to understand how they involve 
immunity and inflammation in susceptible individuals.
The identification of genetic variants may define a specific dis-
ease phenotype to help follow clinical progression and eventually 
develop new targeted therapies.
However, the evidence that genetic factors contribute in 
small part to disease pathogenesis confirms the important 
role of microbial and environmental factors.
Epigenetic mechanisms may affect development and 
progression of IBD, mediating interactions between genome 
and environment. Epigenomics is an emerging field, and 
future studies could provide new insight into the pathogen-
esis of IBD.
The role of miRNA in IBD represents a new pathway for 
discovery of disease mechanisms, diagnostics, and therapeutics.
These new discoveries on the genetics of IBD imply that future 
research on interactions between genes and between genes and 
environment will be essential to better understand the pathogen-
esis of these diseases and more appropriate medical therapy.
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